Consolidated Edison, Inc. vs uniQure N.V. Ordinary Shares — how do they compare? Consolidated Edison, Inc. trades at $110.91 (market cap $39.87B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: Consolidated Edison, Inc. is far larger — about 27.5× uniQure N.V. Ordinary Shares's market cap, and Consolidated Edison, Inc. pays a 3.26% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 76 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ED | QURE | |
|---|---|---|
Market Cap | $39.87B | $1.45B |
Volume | 1,579,122 | 3,323,243 |
Sector | Utilities | Health |
52-Week High | $115.46 | $70.59 |
52-Week Low | $95.37 | $9.03 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $66.72B | $707.46M |
Dividend Yield | 3.26% | — |
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $107.82, up 0.58% on the day, with a bullish technical signal and strong cash flow from operations of $4.80B in 2025. Recent earnings show mixed results, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. The company maintains solid profitability with a net income margin of 12.53% and recently announced a dividend of $0.89 payable in September 2026, highlighting its status as a Dividend Aristocrat.
ED offers stable utility exposure with consistent dividends, but analyst consensus is cautious with 62.96% hold ratings. Risks include high debt levels and regulatory pressures. The stock's current price near the consensus target of $105.56 suggests limited upside, making it suitable for income-focused investors seeking defensive holdings amid market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →